Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

BACKGROUND & AIMS: The development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jitao, Hou, Zhiyun, Liu, Jianxin, Gu, Ye, Wu, Yunhong, Chen, Zhenhuai, Ji, Jiansong, Diao, Shiqi, Qiu, Yuanwang, Zou, Shengqiang, Zhang, Aiguo, Zhang, Nina, Wang, Fengxian, Li, Xue, Wang, Yan, Liu, Xing, Lv, Cheng, Chen, Shubo, Liu, Dengxiang, Ji, Xiaolin, Liu, Chao, Ren, Tao, Sun, Jingwei, Zhao, Zhongwei, Wu, Fazong, Li, Fenxiang, Wang, Ruixu, Yan, Yan, Zhang, Shiliang, Ge, Guohong, Shao, Jiangbo, Yang, Shiying, Liu, Chuan, Huang, Yifei, Xu, Dan, Li, Xiaoguo, Ai, Jingwen, He, Qing, Zheng, Ming-Hua, Zhang, Liting, Xie, Qing, Rockey, Don C., Fallowfield, Jonathan A., Zhang, Wenhong, Qi, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185617/
https://www.ncbi.nlm.nih.gov/pubmed/33905793
http://dx.doi.org/10.1016/j.jhep.2021.04.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185617/
https://www.ncbi.nlm.nih.gov/pubmed/33905793
http://dx.doi.org/10.1016/j.jhep.2021.04.026

Ejemplares similares